2021 ESMO Congress

Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)

https://www.annalsofoncology.org/article/S0923-7534(21)03227-0/fulltext